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The world has finally settled living with Human immunodeficiency Virus (HIV) with no cure discovered 
so far. Yong people with HIV infection under HIV management drugs get married and eventually end up being 
pregnant and bearing babies. The need therefore to investigate the effect of HIV infection and antiretroviral 
drugs on body chemistry especially the hormones concerned with pregnancy and lactation cannot be over 
emphasized as this is important to intervene when necessary for the overall benefit for the mother and child. We 
investigated the effect of anti-retroviral drugs and human immune deficiency virus (HIV) infection on prolactin 
production and stimulation in HIV-infected pregnant women. A total of 120 subjects participated in the study. 
Sixty (group 1) of these subjects were HIV seropositive pregnant women who commenced treatment with 
zidovudine in combination with lamivudine, that is highly anti-retroviral therapy (HAART) at 2nd trimester. The 
2nd group made up of 60 HIV seronegative pregnant women who received no drug and  as control to the study. 
The blood samples of both groups were collected at the beginning of the second and at the end of the third
trimesters. For group 1 (seropositive pregnant women), the blood collection was done just before commencing 
the HAART treatment. The prolactin level of HIV seropositive pregnant women were significantly (P < 0.05) 
lower than the HIV seronegative pregnant women at the 2nd trimester. Also, the prolactin level of HIV 
seropositive pregnant women at 2nd trimester was not significantly increased (P> 0.05) compared with third 
trimester level. The reverse was the case with HIV seronegative pregnant women where prolactin level of 3rd 
trimester was significantly increased when compared with 2nd trimester. HIV infection has prolactin suppressive 
effect on pregnant women and HAART treatment did not significantly raise prolactin level. 
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Prolactin is a protein hormone secreted 
by pituitary mammotrophic cells. High level 
of it can be produced during pregnancy as a 
result of increase in the number of 
mammotrophic cells which is also caused by 
high concentration of circulating oestrogen. 
Over or under production of hormones 
can contribute to a variety of medical 
conditions. Diseases such as HIV that affect 




the whole body can interfere with proper 
endocrine function / secretion, and hormone 
in turn, can affect disease progression 
(Highleyman, 2004). Garcia et al. (2002) 
reported that studies have shown that HIV 
itself could affect the body’s ability to 
produce and maintain hormone levels. 
Patients with acquired immune deficiency 
syndrome (AIDS) have been reported to have 
abnormalities of endocrine organs frequently 
(Fontes et al., 2003). Merenich et al. (1990) 
reported change in levels of prolactin, 
estradiol, testosterone, and thyroxine in HIV 
patients. Ram et al. (2004) stated that there 
was lower free prolactin level in HIV patients 
and pointed out that the high level of prolactin 
in HIV patients was a result of low biologic 
active macro-prolactin in the circulation. 
Montero et al. (2000) reported that high level 
of prolactin in HIV-infected patients does not 
correlate with plasmic viral burden. 
Physiopathology of endocrine dysfunction in 
HIV/AIDS infected patients could not be 
succinctly explained. Verges et al. (1990) 
suspected the involvement of interleukin-1 in 
stimulation of corticotrophin-releasing 
hormone secretion and its direct action on the 
glycoprotein capsule of the virus (gp 120) 
which is similar to that of the hormone. 
 In HIV-infected pregnant women, 
antiretroviral drugs are used to reduce vertical 
transmission of HIV infection from mother to 
child. Suksomboon et al. (2007) stated that 
zidovudine alone or in combination with 
lamivudine and nevirapine monotherapy were 
found to be effective for the prevention of 
mother - to - child transmission of HIV, and 
also were beneficial in reducing the risk of 
infant death. Apart from these beneficial 
effects, antiretroviral drugs can cause adverse 
effects such as anaemia, pre-term delivery 
(Areechokechai et al., 2009). The use of 
antiretroviral drugs has also been associated 
with fluctuation in level of some reproductive 
hormones in HIV seropositve patients. Santro 
et al. (2005) stated that Highly Active 
Antiretroviral Therapy (HAART) increased 
prolactin level in HIV infected patients.  
This study is carried out to investigate 
the effect of antiretroviral drugs on prolactin 
(which is a pregnancy hormone that initiates 
lactation and controls the metabolism of fat, 
carbohydrate, calcium, vitamin D, and foetal 
lung development) among HIV-infected 
pregnant women who were placed on 
antiretroviral drugs. 
 
MATERIALS AND METHODS 
The human subjects used in the study and 
prolactin analysis 
This study was carried out on randomly 
selected one hundred and twenty (120) 
pregnant women attending antenatal clinic in 
General Hospitals in Rivers State, Nigeria. 
Sixty of these women were HIV-seronegative 
(non- infected) and they were regarded as 
control group, while the rest of 60 pregnant 
women were HIV seropositive (HIV-infected) 
as at 2nd trimester of this study. The HIV-
infected women commenced the antiretroviral 
drugs at 2nd trimester after initial sample 
collection. Initial blood sample collection was 
also done at second trimester on control group 
(HIV seronegative pregnant women). Samples 
were also collected from these two groups at 
the end of 3rd trimester of pregnancy to 
estimate the prolactin level using enzyme-
linked immunosorbent-assay (ELISA) method 
as described by (Thorner et al., 1974). 
 
Ethics 
        Ethics approval was obtained from Ethics 
Committee of School of Health Technology, 
Federal University of Technology Owerri, 
Nigeria. Informed consent was also obtained 
from the subjects. 
 
 




Statistical analysis  
The data we generated were analysed 
using statistical package for social sciences 
(SPSS) version 16. Student’s t test was used to 
test the difference between two groups of 




From Table 1 and Figure 1, we 
observed that, there was a significant (p<0.05) 
increase in prolactin level from 104.71 ± 7.68 
ng/ml in the 2nd trimester to 150.75 ± 4.82 
ng/ml in the 3rd trimester of pregnancy among 
non-infected pregnant women, but there was 
no significant (p>0.05) increase in prolactin 
level among seropositive pregnant women 
(from 58.72 ± 5.28 ng/ml in 2nd trimester to 
67.06 ± 4.92 ng/ml) in the 3rd trimester after 
receiving HAART from their 2nd to 3rd 
trimester.  
In Table 1 also, there was a significantly 
(p>0.05) higher level of prolactin in non-
infected pregnant women, 104.71 ± 7.68 
ng/ml, compared to HIV-infected pregnant 
women 58.72 ± 5.28 ng/ml at 2nd trimester. 
This significantly (P<0.05) high level in 
prolactin was also observed when comparison 
was made at 3rd trimester between the non-
infected, (150.75 ± 4.82 ng/ml), and HIV-





Table 1: Comparative prolactin level of HIV-infected and non-infected pregnant women at 2nd and 
3rd trimester.   
 





2nd trimester value (ng/ml) 104.71 ± 7.68 58.72 ± 5.28 P<0.05 
3rd trimester value (ng/ml) 150.75 ± 4.82 67.06 ± 4.92 P<0.05 
P-value P<0.05 P>0.05  





Figure 1: Histogram of means of the prolactin levels at different trimesters. 
 





In this study, we observed that prolactin 
level was significantly increased in non HIV 
infected pregnant women at 2nd and 3rd 
trimesters respectively than in the 
corresponding trimesters of HIV-infected 
group.  The reduction in the prolactin level 
seen among the infected group might be 
attributed to the effect of HIV infection on 
these women. Ram et al. (2004) and co-
workers stated that there was lower free 
prolactin level in HIV patients. Merenish et al. 
(1990) also reported a change in level of 
prolactin and some steroid hormone in patients 
infected with HIV. A more recent study 
conducted by Ogundahunsi et al. (2011) on 
amenorrheic HIV-positive women reported 
significant decrease in leutenizing hormone 
(LH), follicle stimulating hormone (FSH), and 
prolactin level. Although the HIV patients 
used in these studies were non pregnant 
women, their findings were in agreement with 
the present study. HIV infection can directly 
affect endocrine glands thereby causing HIV-
endocrinopathy. It was stated by Sinha et al. 
(2011) that complex interaction between HIV 
infection and endocrine system may be 
manifested as subtle biochemical and 
hormonal perturbation to overt glandular 
failure.  
Normally, prolactin increases with increase in 
gestational age in pregnant women primarily to 
induce milk production at parturition. This was 
observed in non-infected pregnant women in 
this study and the increase from 2nd trimester 
to 3rd trimester was significantly high. There 
was also no significant increase in prolactin 
level at the end of 3rd trimester among HIV-
infected pregnant women who commenced 
antiretroviral treatment when compared with 
that of 2nd trimester. It is known that anti-
retroviral therapy reduces human 
immunodeficiency viral load and up-regulates 
CD4+ count which translates to improved 
health condition of HIV/AIDs sufferers, but 
menstrual irregularities persists despite anti-
retroviral therapy use (Harrington et al., 2000). 
This goes to suggest that HIV/AIDS may 
possess depressive effect on reproductive 
hormones, which the use of anti-retroviral 
agents could not redress. 
  
Conclusion  
In the light of the foregoing, human 
immunodeficiency virus infection may possess 
suppressive effect on prolactin secretion in 
pregnant women and anti retro viral therapy 
did not revise this effect.  
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